A study conducted in Burkina Faso in December 2011, one year after the introduction of MenAfriVac, found that estimates of vaccination coverage did not differ significantly from estimates of coverage during the 2010 campaign.
In December 2011, the U.S. Centers for Disease Control and Prevention worked with the Burkina Faso Ministry of Health to conduct a stratified cluster survey to obtain vaccination coverage estimates by region and age group. The survey found that national coverage for vaccination against serogroup A meningococcal meningitis was 95.9 percent.
The study determined that coverage ranged from 90.8 percent to 98.3 percent in the 13 regions of Burkina Faso. Vaccine coverage was 97.0 percent in children between the ages of two and five, 97.4 percent in children between ages six and 15 and 93.4 percent among people aged 16 to 30 years.
The survey showed that the campaign was a successful introduction of the vaccine through a mass immunization campaign. Population-based coverage surveys are necessary to identify areas of possible under-vaccination and population susceptibility that could be missed by administrative coverage estimates.
MenAfriVac, also known as PsA-TT, is a vaccine that protects against serogroup A meningococcal meningitis. The disease is a major cause of death in Africa's meningitis belt. Phased introduction of MenAfriVac is planned through 2016 throughout the region.